Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Oxford Cannabinoid Technologies Holdings Plc

Oxford Cannabinoid Holdings Plc is the holding company of Oxford Cannabinoid Technologies Ltd, a UK-based pharmaceutical company, which uses cutting-edge technology and a drug development strategy to explore the potential of cannabinoid derivatives, phytocannabinoids, and other drug candidates on the endocannabinoid system, and bring pioneering treatments to market. 

OCT believes it is important to develop a deeper understanding of the molecular actions of cannabinoids. We manage a wide-ranging research program that investigates the medical potential of cannabinoids across different therapeutic areas, with a particular focus on pain.

By employing the latest scientific techniques to provide more evidence that supports the positive effects of cannabinoids, it is our vision to become a global leader in developing cannabinoid-based prescription medication, improving the quality of life for millions of patients.

Casa Verde Capital

Julien Codorniou

On the 4th January 2023 #OCTP submitted a combined clinical trials application for the lead programme, OCT461201, to the UK Medicines & Healthcare products Regulatory Agency (MHRA) and Wales Research Ethics Committee. 

This follows the successful completion of OCTP's extensive pre-clinical work on OCT461201, under the Group's £2.6 million contract research agreement with Aptuit (Verona) SRL.

This Phase I first-in-human clinical trial, due to commence in Q1 2023, which is being funded entirely from OCTP's existing resources, will be conducted in the UK in healthy volunteers, with a single ascending dose. The trial aims to demonstrate safety and tolerability, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The clinical trial is anticipated to complete within Q2 2023.

https://lnkd.in/esJA5q-a

A message from our CEO, Clarissa Sowemimo-Coker.

Longer on the dance floor, very confident and funded until the end of 2023 for @OxCanTech #OCTP

“…We are now entering a period of stability and an exciting time for shareholders…”

https://lnkd.in/evxVy4YE

#OCTP announces a positive trading and operational update for the six months ended 31 October 2022, highlighting continued progress as the lead candidate nears the commencement of clinical trials.
 
Financial and operational targets remain on track and on budget, and the Board remains confident that the Company will achieve the milestones set out in the current development timeline.

Clarissa Sowemimo-Coker, Interim CEO, said: "We are incredibly pleased with the ongoing progress and the fact that we remain on track to meet our financial and operational targets. This is a big achievement and is testament to the adaptability, skill, and "can do" attitude of Dr Valentino Parravicini, his team, and our external partners.
 
"As OCTP nears a critical juncture in its journey to introduce prescription cannabinoid medicines to the US$ multi-billion pain market, we are carefully managing cash and are well placed to deliver on our key objectives. I look forward to updating the market on our continued progress with the half-year results."

https://lnkd.in/epUa2RRF

New Interim CEO Clarissa Sowemimo-Coker speaks to StockBox as #OCTP readies itself to move from the Pre-Clinical into the Clinical Phase with its lead compound.

https://lnkd.in/eZedH5M6

#OCTP interim CEO Clarissa Sowemimo-Coker speaks Proactive as she takes up her new role during an important period for the Company, as it nears the beginning of Phase 1 clinical trials for its lead compound.

https://lnkd.in/edw5S69e

Fantastic night at OBN 2022 in London, celebrating big achievements by small companies, in science and business!

Thank you, Dalriada Drug Discovery, for inviting OCT and sharing with us great company together with the customary (and customized) great science.

#OCTP Chief Scientific Officer Dr. Valentino Parravicini recently joined Proactive to discuss the lead compound as the Company nears readiness for phase 1 clinical trials.

The study will target pain relief in those suffering from chemotherapy-induced peripheral neuropathy (CIPN) and irritable bowel syndrome (IBS), and results are expected to be published in April.

https://lnkd.in/eY8GK5xS

Delighted to welcome Paul Smalley to the Oxford Cannabinoid Technologies Holdings Plc team! #OCTP #team

Missed our latest presentation with StockBox? Catch up below.

#OCTP COO Clarissa Sowemimo-Coker and Dr. Valentino Parravicini discussed targeting neuropathic and visceral pain then had a Q&A session with investors.

https://lnkd.in/eV3DU4_X

COM:OXCANTECH